Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.73Granules India Ltd exhibits a very strong financial profile, marked by exceptional profitability and a secure, low-debt structure. The company is highly effective at turning revenue into profit and generates impressive returns for its investors. Its financial stability is a key strength, as it relies minimally on borrowed funds, making it a low-risk entity in terms of long-term obligations. Furthermore, the company shows outstanding growth potential, with strong projections for future expansion in both revenue and earnings. The primary area of concern is operational efficiency. The company appears to be underutilizing its assets, such as property and inventory, to generate sales. While it is investing heavily in future growth, its current asset management practices show room for improvement. Overall, despite operational inefficiencies, the company's robust profitability, strong growth prospects, and solid financial foundation paint a positive outlook.
Health Score : 7.73Granules India Ltd exhibits a very strong financial profile, marked by exceptional profitability and a secure, low-debt structure. The company is highly effective at turning revenue into profit and generates impressive returns for its investors. Its financial stability is a key strength, as it relies minimally on borrowed funds, making it a low-risk entity in terms of long-term obligations. Furthermore, the company shows outstanding growth potential, with strong projections for future expansion in both revenue and earnings. The primary area of concern is operational efficiency. The company appears to be underutilizing its assets, such as property and inventory, to generate sales. While it is investing heavily in future growth, its current asset management practices show room for improvement. Overall, despite operational inefficiencies, the company's robust profitability, strong growth prospects, and solid financial foundation paint a positive outlook.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
51.77
Industry Median
15.03
Small Cap Median
14.06
P/E RATIO
34.87
P/B RATIO
4.08
Industry Median
2.03
Small Cap Median
2.03
P/S RATIO
3.87
Industry Median
1.38
Small Cap Median
1.38
Others
PEG RATIO
18.85
EV/EBITDA RATIO
16.97
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹837.2 as on Sep 1, 2026.
Growth Score : 10.00The company demonstrates an exceptional outlook for growth across all key areas. Despite some recent volatility, the underlying trend and future projections point to a period of strong expansion. This includes significant anticipated increases in revenue, operating profit, and net income. The company is also expected to grow its asset base, indicating a clear strategy for reinvestment and expansion. This robust growth profile is a major strength and a primary driver of future value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.28 | 19.84 | -0.13 | -0.53 | 19.72 |
| Operating Profit Growth Rate | -15.07 | 25.86 | -6.23 | 10.49 | 25 |
| Earnings Per Share (EPS) Growth | -24.98 | 28.25 | -21.65 | 23.68 | 16.1 |
| Asset Growth Rate | 21.52 | 8.67 | 12.14 | 13.15 | 24.1 |
| Net Income Growth Rate | -24.77 | 25.18 | -21.66 | 23.95 | 18.53 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 4 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 5 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 9 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 10 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 15 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 16 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤5th May 26
Q4 & FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Granules India Ltd. is a vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). A significant player in the global pharmaceutical industry, it focuses on high-volume, off-patent molecules and offers Contract Research and Manufacturing Services (CRAMS), with a strong international presence.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Granules India Ltd's P/E ratio (TTM) is 51.77, compared to the industry median of 15.03 and large cap median of 14.06.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Granules India Ltd's P/B ratio is 4.08, compared to the industry median of 2.03 and large cap median of 2.03.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Granules India Ltd's P/S ratio is 3.87, compared to the industry median of 1.38 and large cap median of 1.38.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Granules India Ltd's PEG ratio is 18.85.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Granules India Ltd's EV/EBITDA ratio is 16.97.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Granules India Ltd's ROE is 11.70%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Granules India Ltd's ROA is 15.35%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Granules India Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Granules India Ltd's operating margin is 22.08%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Granules India Ltd's net margin is 11.09%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Granules India Ltd's current ratio is 1.88.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Granules India Ltd's debt-to-equity ratio is 0.09.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Granules India Ltd's interest coverage ratio is 7.89.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Granules India Ltd's DPS is ₹1.68.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Granules India Ltd's EPS is 16.10.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹837.20. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1987
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs), Contract Research and Manufacturing Services (CRAMS)
Stock Listing: NSE (GRANULES), BSE (532482)
Promoter: C. Krishna Prasad & Family / Granules Promoter Group
1987: Incorporated as Granules India Limited.
1990: Commenced commercial operations.
1991: Initial Public Offering (IPO).
Early 2000s: Expanded into Finished Dosages (FDs).
2007: Formed a joint venture with Ajinomoto OmniChem for custom synthesis (later became part of Granules).
2011: Entered into a strategic alliance with Heritage Pharma (later purchased stake).
Present: Vertically integrated global pharmaceutical company with focus on high-growth segments and international markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Finished Dosages (FDs) | ~50-55% | Operating Profit |
| Active Pharmaceutical Ingredients (APIs) | ~30-35% | Operating Profit |
| Pharmaceutical Formulation Intermediates (PFIs) | ~10-15% | Operating Profit |
Finished Dosages (FDs): Manufactures and markets generic pharmaceutical products globally, including over-the-counter (OTC) and prescription drugs, primarily focusing on high-volume, off-patent molecules.
Active Pharmaceutical Ingredients (APIs): Develops and produces critical raw materials for pharmaceutical formulations, covering a broad range of therapeutic areas.
Pharmaceutical Formulation Intermediates (PFIs): Offers specialized PFI products, providing integrated solutions that bridge the gap between APIs and finished dosages, optimizing customer manufacturing processes.
Contract Research and Manufacturing Services (CRAMS): Provides custom development and manufacturing services for pharmaceutical companies, leveraging its integrated capabilities across APIs and FDs.
C. Krishna Prasad (Chairman & Managing Director): Founder of Granules India, he has over three decades of experience in the pharmaceutical industry and has been instrumental in the company's growth and vertical integration strategy.
Granules Pharmaceuticals, Inc. (USA)
Granules Europe Limited (UK)
Granules Omnichem Private Limited (India)
Granules USA, Inc. (USA)
Granules Contract Manufacturing Limited (India)
Bonus Issue: 1:1 in September 2023. Stock Split: 1:2 in October 2021. No other major recent corporate actions on record.
The Granules India Ltd share price today is ₹837.20 on NSE (GRANULES), as of 26 Sept 2026.
As of 25 Sept 2026, Granules India Ltd share price is ₹837.20, with previous close ₹837.20. Today's range is ₹837.20 to ₹837.20. The 52-week range is ₹531.80 to ₹917.
As of today, Granules India Ltd's market cap is ₹20,762.56 crore (Large Cap).
Granules India Ltd's current P/E ratio is 51.77, compared to the CHEMICALS & PETROCHEMICALS sector average of 31.50.
Granules India Ltd's current P/B ratio is 4.08.
Granules India Ltd's current dividend yield is 0.20%. Last dividend of ₹1.25 per share was declared on 18-Aug-2023.
Granules India Ltd's EPS (TTM) is ₹16.10.
Granules India Ltd. is a vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). A significant player in the global pharmaceutical industry, it focuses on high-volume, off-patent molecules and offers Contract Research and Manufacturing Services (CRAMS), with a strong international presence.
Granules India Ltd is promoted by C. Krishna Prasad & Family / Granules Promoter Group, holding 38.02% as of 25 Sept 2026.
Granules India Ltd is listed on NSE (GRANULES) and BSE (532482). Its next quarterly results are expected on August 2024.
Receivables Turnover Ratio
Quick Ratios
